[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-cervical-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-cervical-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,75,108,129,151,172],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100644680","circulating-cfdna-and-hpv-as-prognostic-biomarkers-for-first-line-recurrent-metastatic-cervical-cancer-100644680",false,"NCT07673211","Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer","A Prognostic Research on First-Line Recurrent and Metastatic Cervical Cancer Using Circulating Cell-Free DNA and Human Papillomavirus Detection","Inclusion Criteria:\n\n1. Histopathologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;\n2. Patients with first recurrent or metastatic cervical cancer (including primary stage IVB disease);\n3. Received standard first-line therapy (TP\u002FTC regimen plus immunotherapy ± bevacizumab);\n4. Achieved complete response (CR) following standard first-line treatment;\n5. Archived pathological biopsy specimens of recurrent\u002Fmetastatic lesions prior to treatment available in our hospital;\n6. Participated in clinical trials of pharmaceutical therapy for first-line recurrent\u002Fmetastatic cervical cancer conducted at our institution;\n7. Voluntarily participates in this study and provides written informed consent;\n8. Agrees to serial peripheral blood collection at scheduled time points;\n9. Willing to complete scheduled follow-up visits;\n10. Aged ≥ 18 years old.\n\nExclusion Criteria:\n\n1. History of other malignant tumors within the past 2 years;\n2. Pregnant or breastfeeding women;\n3. Severe concomitant diseases, including: cardiovascular diseases (e.g., uncontrolled heart failure, unstable angina, etc.); pulmonary diseases (e.g., severe chronic obstructive pulmonary disease, interstitial pneumonia and other conditions impairing respiratory function); hepatic and renal dysfunction (e.g., decompensated liver cirrhosis, severe renal failure requiring dialysis, etc.);\n4. Refusal to sign informed consent;\n5. Refusal to undergo serial blood collection.","FEMALE","18 Years",{"count":19,"type":20},60,"ESTIMATED","3 Years","OBSERVATIONAL","Primary Objective of this study: To investigate the correlation between longitudinal quantitative dynamics of circulating tumor DNA (ctDNA) and HPV-derived cell-free DNA (HPV cfDNA) in peripheral blood and clinical prognosis among patients with recurrent and metastatic cervical cancer who achieved complete response following standard first-line systemic therapy.",[25,26,27],"Cervical Cancer","Recurrent Cervical Cancer","Metastatic Cervical Cancer",[29,30,31,32,33],"Cervical cancer","ctDNA","HPV cfDNA","Complete response","Prognosis","NOT_YET_RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":20},"2026-06",{"date":42,"type":20},"2029-12",{"name":44,"class":45},"Zhejiang Cancer Hospital","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100629244","phase-2-pd-1-programmed-death-1-versus-pd-l1-programmed-death-ligand-1-immune-check-point-inhibitors-combined-with-chemotherapy-with-or-without-bevacizumab-in-patients-with-metastatic-persistent-or-recurrent-cervical-cancer-100629244","NCT07472153","PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","To Validate, Develop and Implement The Scope of Medical Care for Metastatic, Persistent and Recurrent Cervical Cancer Using The Method of Chemoimmunotargeted Therapy","Inclusion Criteria:\n\n* Age ≥18-≤75 years.\n* Histologically confirmed diagnosis.\n* One of the forms of the cervical cancer:\n\n  1. Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018);\n  2. Persistent cervical cancer (primary incurability after radical treatment for stages IIB-IVA cervical cancer according to FIGO 2018);\n  3. Reccurent cervical cancer (first recurrence after completed radical treatment for IA-IVB cervical cancer according to FIGO 2018).\n* Availability of material for determining PD-L-1 expression for immunotherapy candidates.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* No contraindications to chemotherapy, immunotherapy, or bevacizumab.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of another active malignant invasive neoplasm.\n* Pregnancy or lactation period.","75 Years",{"count":55,"type":20},120,"INTERVENTIONAL",[58,59],"PHASE2","PHASE3","This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.",[27,62,26],"Persistent Cervical Cancer","RECRUITING","2026-05-26",{"date":66,"type":38},"2026-05-28",{"date":68,"type":38},"2025-07-01",{"date":70,"type":20},"2033-06-30",{"name":72,"class":73},"N.N. Alexandrov National Cancer Centre","OTHER_GOV",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":82,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":56,"phases":85,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100528160","phase-2-prgn-2009-in-combination-with-pembrolizumab-in-patients-with-recurrent-or-metastatic-cervical-cancer-100528160","NCT06157151","PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","A Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer.","Inclusion Criteria:\n\n* Age 18 years and older.\n* Recurrent or metastatic cervical cancer (histologically or cytologically confirmed)\n* Must have been treated with pembrolizumab, either as monotherapy or in combination, for atleast 6 weeks.\n* Subjects must have histologically or cytologically confirmed HPV positive disease\n* Measurable disease that can be accurately measured by RECIST v1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy ≥ 12 weeks from the time of enrollment.\n* Must have adequate organ function\n* Negative serum pregnancy test. Women of child-bearing potential (WOCBP) must agree to use adequate contraception prior to study entry and for at least 6 months following completion of study treatment.\n* All patients must have the ability to understand and willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Prior chemotherapy, targeted therapy within 14 days; monoclonal antibody within 4 weeks; unresolved AEs.\n* Immunodeficiency, active autoimmune disease on immunosuppression, or immunosuppressive therapy within 7 days. HIV eligible with disease control.\n* Active hepatitis B (HBsAg+) or hepatitis C (HCV RT-PCR+) within 30 days of enrollment.\n* History of non-infectious pneumonitis or interstitial lung disease.\n* History of endocrine autoimmune disease (exceptions: treated Graves' disease; hypothyroidism on replacement).\n* Live vaccine within 30 days prior to first dose.\n* Patients with presence of other active malignancy within 1 year prior to study entry\n* Known Central Nervous System (CNS) disease\n* Has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients.\n* Known history of active tuberculosis (TB, Bacillus tuberculosis).\n* Pregnant and lactating women are excluded from this study.\n* Patients with a history of solid organ transplant.\n* Patients currently participating in a study of an investigational agent or have used an investigational device within 4 weeks prior to the first dose of study treatment.\n* Patients, who in the opinion of the investigator, may not be able to comply with the monitoring requirements of the study.","ALL",{"count":84,"type":20},24,[58],"This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.",[25,88,89,90,27],"HPV-Related Carcinoma","HPV-Related Malignancy","Recurrent Cervical Carcinoma",[92,25,93,94,95,96],"Human Papilloma Virus","Pembrolizumab","Therapeutic Vaccine","Cervix Cancer","Resistance to Checkpoint Inhibitors","2026-04-20",{"date":99,"type":38},"2026-04-23",{"date":101,"type":38},"2025-11-11",{"date":103,"type":20},"2030-11-30",{"name":105,"class":106},"Precigen, Inc","INDUSTRY",3,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":56,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":74},"100625139","phase-3-a-study-of-shr-a2102-versus-investigators-choice-of-chemotherapy-in-patients-with-platinum-based-chemotherapy-and-pd-l1-inhibitor-treatment-failed-recurrent-or-metastatic-cervical-cancer-100625139","NCT07418749","A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","An Open-label, Randomized, Controlled, Multicenter, Phase III Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","Inclusion Criteria:\n\n1. Participate in the study voluntarily, sign the informed consent form.\n2. Histologically or cytologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma that is deemed unsuitable for radical surgery and\u002For radical radiotherapy or chemoradiotherapy.\n3. Provide primary or metastatic tumor samples.\n4. At least one measurable lesion (RECIST version 1.1).\n5. ECOG 0\\~ 1.\n6. With adequate organ functions.\n7. Expected overall survival is ≥12 weeks.\n\nExclusion Criteria:\n\n1. With known untreated or active central nervous system (CNS) tumor metastasis, or a history of or current leptomeningeal metastasis.\n2. With symptomatic, poorly controlled, or moderate-to-severe pleural effusion, pericardial effusion, or ascites.\n3. With a history of or concurrent other malignant tumor(s).\n4. Participants with gastrointestinal perforation or fistula, urogenital fistula, or those at risk of fistula within 3 months prior to randomization.\n5. With known or suspected interstitial lung disease.\n6. With intestinal obstruction or signs\u002Fsymptoms suggestive of intestinal obstruction within 3 months prior to randomization.\n7. With poorly controlled cardiac clinical symptoms or diseases.\n8. Experienced arterial\u002Fvenous thromboembolic events within 3 months prior to randomization.\n9. With severe infections occurring within 1 month prior to randomization.\n10. With active hepatitis B (defined as positive hepatitis B surface antigen \\[HBsAg\\] test and hepatitis B virus \\[HBV\\] DNA ≥500 IU\u002FmL at screening) or active hepatitis C (defined as positive hepatitis C virus antibody \\[HCV-Ab\\] test and detectable hepatitis C virus \\[HCV\\] RNA at screening).\n11. With active tuberculosis infection within 1 year prior to randomization, or a history of active tuberculosis infection more than 1 year ago without proper treatment.\n12. With a history of immunodeficiency, including a positive human immunodeficiency virus (HIV) test, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.\n13. Have received systemic anti-tumor therapy within 28 days prior to randomization.\n14. With uncontrolled psychiatric disorders, or known history of alcoholism, drug abuse, or substance dependence, incarceration, or other conditions that may affect the completion of study procedures.\n15. Any other condition that, in the judgment of the investigator, may increase the risk associated with study participation, interfere with the interpretation of study results, or make the participant unsuitable for the study.",{"count":116,"type":20},398,[59],"The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.",[26,27],"2026-04-03",{"date":122,"type":38},"2026-04-06",{"date":124,"type":38},"2026-03-30",{"date":126,"type":20},"2028-12",{"name":128,"class":106},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":56,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100428963","phase-2-pembrolizumab-and-lenvatinib-in-advanced-cervical-cancer-100428963","NCT04865887","Pembrolizumab and Lenvatinib in Advanced Cervical Cancer","A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer","Inclusion Criteria:\n\n1. Female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of locally advanced or metastatic cervical cancer will be enrolled in this study.\n2. Patients with progression or intolerance to at least one line of therapy in the locally advanced or metastatic setting will be eligible for this study.\n3. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n   1. Not a woman of childbearing potential (WOCBP) as defined OR\n   2. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.\n4. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n5. Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n6. Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue. Note: If submitting unstained cut slides, newly cut slides should be submitted to the testing laboratory within 14 days from the date slides are cut.\n7. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 28 days prior to the date of treatment initiation.\n8. Have adequate organ function as defined. Specimens must be collected within 28 days prior to the start of study treatment.\n\n   1. Absolute neutrophil count (ANC) ≥1500\u002FµL\n   2. Platelets ≥100 000\u002FµL\n   3. Hemoglobin ≥9.0 g\u002FdL\n   4. Creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 × ULN OR ≥30 mL\u002Fmin for participant with creatinine levels \\>1.5 × institutional ULN\n   5. Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \\>1.5 × ULN\n   6. AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver metastases)\n   7. International normalized ratio (INR) OR prothrombin time (PT), Activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants\n\nExclusion Criteria:\n\n1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment initiation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent.\n3. Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be eligible.Note: If participant received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting study treatment.\n4. Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease.\n5. Has received a live vaccine or live attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.\n6. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.\n7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n8. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma) that have undergone potentially curative therapy are not excluded.\n9. Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.\n10. Has severe hypersensitivity (≥Grade 3) to pembrolizumab or lenvatinib and\u002For any of their excipients.\n11. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n12. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n13. Has an active infection requiring systemic therapy.\n14. Has a known history of Human Immunodeficiency Virus (HIV).\n15. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.\n16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n17. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n18. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n19. Has uncontrolled blood pressure (BP) (Systolic BP\\>140 mmHg or diastolic BP\\>90 mmHg) in spite of an optimized regimen of antihypertensive medication.\n20. Has electrolyte abnormalities that have not been corrected.\n21. Has significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening.\n22. Has bleeding or thrombotic disorders or subjects at risk for severe hemorrhage. The degree of tumor invasion\u002Finfiltration of major blood vessels (e.g. carotid artery) should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage\u002Fnecrosis following lenvatinib therapy.\n23. Subjects having \\> 1+ proteinuria on urine dipstick testing unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is \\\u003C1 g\u002F24 hours.\n24. Has gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib.\n25. Prolongation of QTc interval to \\>480 ms.",{"count":137,"type":20},35,[58],"This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.",[25,27],"2025-10-03",{"date":143,"type":38},"2025-10-07",{"date":145,"type":38},"2022-10-07",{"date":147,"type":20},"2026-07",{"name":149,"class":45},"Georgetown University",4,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":158,"targetDuration":160,"studyType":22,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":4},"100607308","ql706--chemo--bevacizumab-in-anti-pd-l1-resistant-rm-cervical-cancer-100607308","NCT07186868","QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R\u002FM Cervical Cancer","A Prospective, Open-Label, Single-Arm Study of Iparomlimab and Toripalimab Plus Nab-Paclitaxel With or Without Bevacizumab in Recurrent\u002FMetastatic Cervical Cancer Progressed on Anti-PD-(L)1 Therapy","Inclusion Criteria:\n\n* Female patients aged 18 to 75 years.\n* Histologically, pathologically, or radiologically confirmed recurrent or metastatic cervical cancer.\n* At least one measurable lesion as defined by RECIST 1.1 (non-nodal lesion longest diameter ≥10 mm or lymph node short axis ≥15 mm).\n* ECOG performance status of 0 or 1.\n* Life expectancy ≥12 weeks.\n* Disease progression after receiving at least one prior anti-PD-1\u002FPD-L1 monoclonal antibody therapy (alone or in combination).\n* Adequate organ function within 14 days before enrollment:\n\nAbsolute neutrophil count (ANC) \\>1.5 × 10⁹\u002FL Platelets \\>100 × 10⁹\u002FL Hemoglobin \\>100 g\u002FL Serum total bilirubin \\\u003C1.5 × ULN ALT and AST \\\u003C3 × ULN Creatinine clearance (CCr) \\>60 mL\u002Fmin\n\n* Voluntarily sign the informed consent form, able to understand and comply with study requirements.\n\nExclusion Criteria:\n\n* Known allergy to any component of the study drugs.\n* Prior treatment with any CTLA-4 targeting medication.\n* Adverse reactions from previous anti-cancer therapy have not recovered to ≤ Grade 1 (per CTCAE v5.0) (except for toxicities without safety risk per investigator's judgment, e.g., alopecia).\n* History of other malignancies within the past 5 years, except for cured malignancies.\n* Severe comorbid conditions, including but not limited to:\n\nExtensive interstitial lung disease requiring medication. Active or uncontrolled infections (e.g., tuberculosis, HIV). Decompensated liver disease, active hepatitis, or active bleeding. History of cerebrovascular accident or pulmonary embolism. Active, known, or suspected autoimmune diseases. Active infection requiring systemic anti-infective therapy.\n\n* Ascites with depth \\>5 cm measured by ultrasound or CT, OR ascites causing severe symptoms (e.g., abdominal distension, dyspnea, circulatory dysfunction) significantly impacting physical function or study safety.\n* Pregnant, planning pregnancy, or lactating women.\n* Any other condition deemed by the investigator as unsuitable for participation in this study.",{"count":159,"type":20},25,"2 Years","This is a clinical research study for women with recurrent or metastatic cervical cancer whose disease has progressed after prior treatment with a PD-1\u002FPD-L1 inhibitor immunotherapy.\n\nThe study will evaluate the effectiveness and safety of a new combination treatment consisting of iparvolimab and tuvonralimab (QL1706)-a dual-targeting immunotherapy drug-along with chemotherapy (nab-paclitaxel) with or without bevacizumab, an anti-angiogenic drug that may help prevent tumor growth.\n\nApproximately 25 participants will be enrolled in this open-label, single-arm study. All participants will receive the study treatment for up to 6 cycles, followed by maintenance therapy until disease progression, unacceptable side effects, or other reasons for stopping treatment.\n\nThe main goal of the study is to see how many patients respond to the treatment (Objective Response Rate, ORR). Other goals include measuring how long the response lasts, how long patients live without the cancer getting worse, and overall survival. Safety and quality of life will also be closely monitored.\n\nThis study is for women aged 18-75 who have previously received PD-1\u002FPD-L1 treatment and whose cancer has worsened. Participants must be in generally good health with adequate organ function and no other active cancers.\n\nThe study will be conducted at a single center in China. All participants will provide written informed consent before joining the study.",[26,27],"2025-09-16",{"date":165,"type":38},"2025-09-22",{"date":167,"type":20},"2025-10-15",{"date":169,"type":20},"2027-12-30",{"name":171,"class":45},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100575354","study-on-disease-characteristics-and-treatment-in-locally-advanced-or-recurrent--metastatic-cervical-cancer-in-italy-100575354","NCT06771193","Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent \u002F Metastatic Cervical Cancer in Italy","RETRACE Study - Retrospective Observational Study Evaluating Disease Characteristics and Treatment Landscape of High-risk Locally Advanced (LA) or Recurrent \u002F Metastatic (R\u002FM) Cervical Cancer in Italy","RETRACE","Inclusion Criteria:\n\n* Patient (or their legally acceptable representatives) must have signed and dated the Informed Consent \\& Privacy Form (ICF)\n* Age ≥18 years\n* Diagnosis of a cervical cancer\n* Locally advanced stage (not suitable for curative surgery) or recurrent or metastatic disease\n* Any treatment received between January 2018 and December 2021 for advanced disease\n\nExclusion Criteria:\n\n* Patients participating in a pharmacological clinical trial for the treatment of advanced disease\n* Patients who participated in a clinical trial\n* Patients who were administered with Pembrolizumab, Olaparib or Levantinib or medications from these class of drugs",{"count":181,"type":20},200,"Multicenter, Observational, Retrospective charts review. Observational study with descriptive purpose only. Retrospective data capture in consecutive patients diagnosed with CC who attended the Oncologic Clinics from Jan 2018 to Dec 2021 (using medical records, either electronic or not), inserted in eCRF and analyzed.",[25,184,26,27],"Locally Advanced Cervical Cancer","2025-07-16",{"date":187,"type":38},"2025-07-20",{"date":189,"type":38},"2024-12-17",{"date":191,"type":20},"2025-12",{"name":193,"class":106},"MSD Italia S.r.l.",11]